Celtaxsys completes Phase I study of CTX-4430 in cystic fibrosis patients

US-based clinical stage drug firm Celtaxsys has completed the Phase I clinical trial of its lead clinical stage drug candidate, CTX-4430 to treat patients with cystic fibrosis (CF) lung disease.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news